The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
Recruitment of two doctors for the R&D area under the Torres Quevedo Programme 2020
ROVI is a company committed to innovation, allowing it to safeguard its portfolio composed of over 500 patent dossiers, 408 of which have...
1 min
30/10/2020